FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130883917> ?p ?o ?g. }

• W2130883917 endingPage "937" @default.
• W2130883917 startingPage "932" @default.
• W2130883917 abstract "BackgroundCatheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of butylscopolamine in treating CRBD after urological surgeries.MethodsAdult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the butylscopolamine group (n=28) was administered butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug.ResultsThe severity of CRBD observed in the butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the butylscopolamine group, P<0.01]. Rescue analgesics were required less in the butylscopolamine group than in the control group (P=0.001). Adverse events were comparable between the two groups.ConclusionButylscopolamine 20 mg administered i.v. after complaining CRBD during recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries. Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of butylscopolamine in treating CRBD after urological surgeries. Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the butylscopolamine group (n=28) was administered butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. The severity of CRBD observed in the butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the butylscopolamine group, P<0.01]. Rescue analgesics were required less in the butylscopolamine group than in the control group (P=0.001). Adverse events were comparable between the two groups. Butylscopolamine 20 mg administered i.v. after complaining CRBD during recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries." @default.
• W2130883917 created "2016-06-24" @default.
• W2130883917 creator A5039108761 @default.
• W2130883917 creator A5048488282 @default.
• W2130883917 creator A5060257314 @default.
• W2130883917 creator A5069411683 @default.
• W2130883917 creator A5072387139 @default.
• W2130883917 creator A5078615122 @default.
• W2130883917 creator A5078916819 @default.
• W2130883917 creator A5087113157 @default.
• W2130883917 date "2013-12-01" @default.
• W2130883917 modified "2023-09-27" @default.
• W2130883917 title "Efficacy of butylscopolamine for the treatment of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study" @default.
• W2130883917 cites W1965771776 @default.
• W2130883917 cites W1971081113 @default.
• W2130883917 cites W1980107403 @default.
• W2130883917 cites W1988958818 @default.
• W2130883917 cites W1999825265 @default.
• W2130883917 cites W2009562887 @default.
• W2130883917 cites W2015770414 @default.
• W2130883917 cites W2017602106 @default.
• W2130883917 cites W2032527351 @default.
• W2130883917 cites W2035874674 @default.
• W2130883917 cites W2060193818 @default.
• W2130883917 cites W2072728465 @default.
• W2130883917 cites W2074323366 @default.
• W2130883917 cites W2092477693 @default.
• W2130883917 cites W2107135805 @default.
• W2130883917 cites W2108423794 @default.
• W2130883917 cites W2118048528 @default.
• W2130883917 cites W2142148858 @default.
• W2130883917 doi "https://doi.org/10.1093/bja/aet249" @default.
• W2130883917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23869107" @default.
• W2130883917 hasPublicationYear "2013" @default.
• W2130883917 type Work @default.
• W2130883917 sameAs 2130883917 @default.
• W2130883917 citedByCount "45" @default.
• W2130883917 countsByYear W21308839172014 @default.
• W2130883917 countsByYear W21308839172015 @default.
• W2130883917 countsByYear W21308839172016 @default.
• W2130883917 countsByYear W21308839172017 @default.
• W2130883917 countsByYear W21308839172018 @default.
• W2130883917 countsByYear W21308839172019 @default.
• W2130883917 countsByYear W21308839172020 @default.
• W2130883917 countsByYear W21308839172021 @default.
• W2130883917 countsByYear W21308839172022 @default.
• W2130883917 countsByYear W21308839172023 @default.
• W2130883917 crossrefType "journal-article" @default.
• W2130883917 hasAuthorship W2130883917A5039108761 @default.
• W2130883917 hasAuthorship W2130883917A5048488282 @default.
• W2130883917 hasAuthorship W2130883917A5060257314 @default.
• W2130883917 hasAuthorship W2130883917A5069411683 @default.
• W2130883917 hasAuthorship W2130883917A5072387139 @default.
• W2130883917 hasAuthorship W2130883917A5078615122 @default.
• W2130883917 hasAuthorship W2130883917A5078916819 @default.
• W2130883917 hasAuthorship W2130883917A5087113157 @default.
• W2130883917 hasBestOaLocation W21308839171 @default.
• W2130883917 hasConcept C126322002 @default.
• W2130883917 hasConcept C141071460 @default.
• W2130883917 hasConcept C142724271 @default.
• W2130883917 hasConcept C168563851 @default.
• W2130883917 hasConcept C197934379 @default.
• W2130883917 hasConcept C204787440 @default.
• W2130883917 hasConcept C27081682 @default.
• W2130883917 hasConcept C2777343469 @default.
• W2130883917 hasConcept C2777397205 @default.
• W2130883917 hasConcept C2781267111 @default.
• W2130883917 hasConcept C42219234 @default.
• W2130883917 hasConcept C43376680 @default.
• W2130883917 hasConcept C71924100 @default.
• W2130883917 hasConceptScore W2130883917C126322002 @default.
• W2130883917 hasConceptScore W2130883917C141071460 @default.
• W2130883917 hasConceptScore W2130883917C142724271 @default.
• W2130883917 hasConceptScore W2130883917C168563851 @default.
• W2130883917 hasConceptScore W2130883917C197934379 @default.
• W2130883917 hasConceptScore W2130883917C204787440 @default.
• W2130883917 hasConceptScore W2130883917C27081682 @default.
• W2130883917 hasConceptScore W2130883917C2777343469 @default.
• W2130883917 hasConceptScore W2130883917C2777397205 @default.
• W2130883917 hasConceptScore W2130883917C2781267111 @default.
• W2130883917 hasConceptScore W2130883917C42219234 @default.
• W2130883917 hasConceptScore W2130883917C43376680 @default.
• W2130883917 hasConceptScore W2130883917C71924100 @default.
• W2130883917 hasIssue "6" @default.
• W2130883917 hasLocation W21308839171 @default.
• W2130883917 hasLocation W21308839172 @default.
• W2130883917 hasOpenAccess W2130883917 @default.
• W2130883917 hasPrimaryLocation W21308839171 @default.
• W2130883917 hasRelatedWork W1975511334 @default.
• W2130883917 hasRelatedWork W1982674655 @default.
• W2130883917 hasRelatedWork W2010112604 @default.
• W2130883917 hasRelatedWork W2048131422 @default.
• W2130883917 hasRelatedWork W2085947633 @default.
• W2130883917 hasRelatedWork W2413034325 @default.
• W2130883917 hasRelatedWork W2413381826 @default.
• W2130883917 hasRelatedWork W2521993632 @default.
• W2130883917 hasRelatedWork W2895649283 @default.
• W2130883917 hasRelatedWork W3212102112 @default.

• next